Novel approach with intratracheal administration of microgelatin hydrogel microspheres incorporating basic fibroblast growth factor for rescue of rats with monocrotaline-induced pulmonary hypertension

被引:6
|
作者
Hirose, Keiichi [2 ]
Marui, Akira
Arai, Yoshio
Kushibiki, Toshihiro [4 ]
Kimura, Yu [4 ]
Sakaguchi, Hisashi
Yuang, Huang
Chandra, B. I. R. Shyamal
Ikeda, Tadashi
Amano, Shigeru
Tabata, Yasuhiko [4 ]
Komeda, Masashi [1 ,3 ]
机构
[1] Kyoto Univ, Dept Cardiovasc Surg, Grad Sch Med, Sakyo Ku, Kyoto 6068507, Japan
[2] Shizuoka Childrens Hosp, Dept Cardiovasc Surg, Shizuoka, Japan
[3] Kyoto Univ, Lab Sci, Grad Sch Med, Kyoto 6068507, Japan
[4] Kyoto Univ, Inst Frontier Med Sci, Kyoto 6068507, Japan
来源
关键词
D O I
10.1016/j.jtcvs.2008.05.038
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Pulmonary hypertension is a life-threatening disease, and alternative strategies are essential for patients with critical pulmonary hypertension. We developed a new procedure using microgelatin hydrogel microspheres incorporating basic fibroblast growth factor (mGHMs/bFGF)for intratracheal administration and evaluated the effect of a single intratracheal administration ofmGHMs/bFGF on ratswith monocrotaline-induced pulmonary hypertension. Methods: Monocrotaline was injected into 54 rats simultaneously with intratracheal administration of plain mGHMs (vehicle group), bFGF in solution form (free-bFGF group), mGHMs/bFGF (mGHMs/bFGF group), and plain saline with subcutaneous injection of saline instead of monocrotaline (control group, n = 18). Three weeks after the administration, 48 rats (n 12 from each group) were subjected to hemodynamic and histologic evaluations. Survival was assessed in 6 rats of each group 10 weeks after the intratracheal administration. Results: The mGHMs/bFGF group showed significantly lower right ventricular/left ventricular pressure ratios at 3 weeks than the vehicle and free-bFGF groups (0.35 +/- 0.04, 0.54 +/- 0.11, 0.58 +/- 0.21, and 0.36 +/- 0.05 for the control, vehicle, free-bFGF, and mGHMs/bFGF groups, respectively; P<. 01). Histologically, the mGHMs/ bFGF group had a significantly higher number of vessels (diameter >= 50 mu m) than the other groups (5.3 +/- 2.6, 4.6 +/- 2.8, 7.3 +/- 2.5, and 18.9 +/- 7.0 vessels/mm(2), respectively; P<. 01). Ten weeks after the intratracheal administration, 6 (100.0%) rats had survived in the control group, and 1 (16.7%) survived in the vehicle, 0 (0%) in the free-bFGF, and 5 (83.3%) in the mGHMs/bFGF groups (n 6 each). Conclusions: A single intratracheal administration of mGHMs/bFGF increased the number of vessels in the lung and ameliorated survival and hemodynamics in rats with monocrotaline-induced pulmonary hypertension.
引用
收藏
页码:1250 / 1256
页数:7
相关论文
共 50 条
  • [1] Novel approach to rescue severe pulmonary hypertension (PH) with intratracheal administration of micro gelatin hydrogel microspheres incorporating basic fibroblast growth factor (bFGF)
    Hirose, Keiichi
    Ikeda, Tadashi
    Marul, Akira
    Arai, Yoshio
    Kushibiki, Toshihiro
    Kimura, Yu
    Sakaguchi, Hisashi
    Yuang, Huang
    Chandra, Shyamal B.
    Tabata, Yasuhiko
    Komeda, Masashi
    CIRCULATION, 2006, 114 (18) : 392 - 392
  • [2] Intravenous infusion of basic fibroblast growth factor prevents monocrotaline-induced pulmonary hypertension in rats
    Iwakura, A
    Fujita, M
    Tabata, Y
    Ikai, A
    Yanazume, T
    Komeda, M
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (02) : 270A - 270A
  • [3] BASIC FIBROBLAST GROWTH-FACTOR ALTERATIONS DURING DEVELOPMENT OF MONOCROTALINE-INDUCED PULMONARY-HYPERTENSION IN RATS
    ARCOT, SS
    FAGERLAND, JA
    LIPKE, DW
    GILLESPIE, MN
    OLSON, JW
    GROWTH FACTORS, 1995, 12 (02) : 121 - 130
  • [4] INCREASED HEPATOCYTE GROWTH FACTOR IN MONOCROTALINE-INDUCED PULMONARY HYPERTENSION IN RATS
    Radik, M.
    Kmecova, Z.
    Veteskova, J.
    Malikova, E.
    Krenek, P.
    Klimas, J.
    JOURNAL OF HYPERTENSION, 2018, 36 : E21 - E21
  • [5] Growth factor expression and effects of amrinone in monocrotaline-induced pulmonary hypertension in rats
    Burch, GH
    Jensen, LR
    Pappas, J
    Hammond, EH
    Banner, W
    Shaddy, RE
    BIOCHEMICAL AND MOLECULAR MEDICINE, 1996, 58 (02) : 204 - 210
  • [6] Intratracheal mesenchymal stem cell administration attenuates monocrotaline-induced pulmonary hypertension and endothelial dysfunction
    Baber, Syed R.
    Deng, Weiwen
    Master, Ryan G.
    Bunnell, Bruce A.
    Taylor, Bradley K.
    Murthy, Subramanyam N.
    Hyman, Albert L.
    Kadowitz, Philip J.
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2007, 292 (02): : H1120 - H1128
  • [7] Intratracheal administration of prostacyclin analog-incorporated nanoparticles ameliorates the development of monocrotaline-induced pulmonary artery hypertension in rats
    Akagi, S.
    Nakamura, K.
    Matsubara, H.
    Ito, H.
    EUROPEAN HEART JOURNAL, 2014, 35 : 761 - 762
  • [8] Efficacy of novel phosphodiesterase inhibitors in rats with monocrotaline-induced pulmonary hypertension
    Bruse, Kristy D.
    Pahl, Andreas
    JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2012, 66 (02) : 194 - 194
  • [9] Coupling Factor 6 Is Upregulated in Monocrotaline-induced Pulmonary Arterial Hypertension in Rats
    Li, Nannan
    Yin, Jie
    Cai, Weidong
    Liu, Jingjing
    Zhang, Na
    Yan, Suhua
    Song, Lucheng
    Li, Xiaolu
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2016, 352 (06): : 631 - 636
  • [10] Effect of chronic administration of aminoguanidine on the reactivity of pulmonary vessels in rats with monocrotaline-induced pulmonary hypertension
    Bonartsev, A
    Slavutskaja, A
    Postnikov, A
    Medvedeva, N
    JOURNAL OF HYPERTENSION, 2004, 22 : S30 - S30